The distribution of observed mutations was consistent with prior reports (Figure 2): 50% (19 of 38 patients) had a KRAS mutant tumor, 16% (6 of 38 patients) had a PIK3CA mutation, 8% (3 of 38 patients) showed a mutation in BRAF, and none showed an EGFR mutation. This evidence concerns the gene BRAF and neoplasm.